Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
February 19 2019 - 7:00AM
Phase 2 Clinical Study Results in Treatment of
Common Warts Selected for Oral Presentations
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company, today announced that posters
summarizing the clinical results of a Phase 2 clinical trial of its
investigational medicine, A-101 45% topical solution for the
treatment of common warts, have been selected for oral presentation
during the American Academy of Dermatology (AAD) Annual Meeting to
be held March 1 - 5, 2019 in Washington, D.C.
The details of the e-posters with oral presentations are as
follows:
- Long-Term Efficacy and Safety of Hydrogen Peroxide Topical
Solution, 45% (w/w) in Patients with Common Warts: Posttreatment
Results from the Phase 2 WART-203 Trial
- Poster 10224
- Date and time of oral presentation: Saturday, March 2, 10:25
a.m. to 10:30 a.m.
- Location of oral presentation: Hall H, ePoster Presentation
Center 2
- Efficacy and Safety of Hydrogen Peroxide Topical Solution, 45%
(w/w) for Treatment of Common Warts: 8-Week Results from the Phase
2 WART-203 Trial
- Poster 10150
- Date and time of oral presentation: Sunday, March 3, 10:20 a.m.
to 10:25 a.m.
- Location of oral presentation: Hall H, ePoster Presentation
Center 1
In addition, the following original abstracts were accepted for
e-poster presentation during the meeting:
- Poster 10235 - Rater Reliability Testing of the Physician Wart
Assessment for Common Warts: A Noninterventional, Observational
Study
- Poster 10497 - Effectiveness of Hydrogen Peroxide Topical
Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on
the Trunk, Extremities, and Face: Results of a Phase 2, Randomized,
Double-Blind, Vehicle-Controlled, Parallel Group Study
- Poster 10513 - Safety of Hydrogen Peroxide Topical Solution 40%
and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk,
Extremities, and Face: Results of a Phase 2, Randomized,
Double-Blind, Vehicle-Controlled, Parallel-Group Study
- Poster 10527 - Onset of Treatment Effectiveness with Hydrogen
Peroxide Topical Solution 40% and 45% (w/w) in Patients with
Seborrheic Keratoses on the Trunk, Extremities and Face: Results of
a Phase 2, Randomized, Double-Blind, Vehicle-Controlled,
Parallel-Group Study
About A-101 45% Topical Solution
A-101 45% topical solution, an investigational medicine
for the treatment of common warts, is a proprietary, stabilized,
high concentration hydrogen peroxide topical solution, 45% (w/w),
also referred to as HP45. It is being developed as a topical,
non-invasive treatment for self-administration or administration by
a caregiver. If approved, A-101 45% topical solution would be the
first prescription medicine approved by the FDA for the treatment
of common warts.
About Common Warts
Common warts, also called verruca vulgaris, are skin growths
caused by a virus infecting the top layer of the skin. They affect
an estimated 22 million Americans each year with a higher incidence
in children than adults. Common warts are often skin-colored and
feel rough but can be darker and smooth. Symptoms include
pain, bleeding, itching, and burning. Common warts are contagious
and may interfere with social activities, cause embarrassment, and
carry a social stigma. Each year, over 2 million people in the U.S.
are diagnosed with common warts during a visit to a health care
professional.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology. Aclaris’
focus on market segments with no FDA-approved medications or where
treatment gaps exist has resulted in the first FDA-approved
treatment for raised seborrheic keratoses and several clinical
programs to develop medications for the potential treatment of
common warts, alopecia areata, and vitiligo. For additional
information, please visit www.aclaristx.com and follow Aclaris on
LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding Aclaris’ clinical development of its investigational
medicine, A-101 45% topical solution. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris' reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in the Risk Factors section of Aclaris' Annual Report on
Form 10-K filed for the year ended December 31, 2017, Aclaris’
Quarterly Report on Form 10-Q for the quarter ended September 30,
2018 and other filings Aclaris makes with the U.S. Securities and
Exchange Commission from time to time. These documents are
available under the "SEC filings" section of the Investors page of
Aclaris' website at http://www.aclaristx.com. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Aclaris as of the date of this
release, and Aclaris assumes no obligation to, and does not intend
to, update any forward-looking statements, whether as a result of
new information, future events or otherwise.
Aclaris Therapeutics Contacts
Investor ContactMichael Tung, M.D.Senior Vice PresidentCorporate
Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President, Corporate
Communications484-321-5559media@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024